LEPU ScienTech Medical Plans Up to RMB100 Million H-Share Buyback

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H ( (HK:2291) ) has provided an announcement.

LEPU ScienTech Medical Technology (Shanghai) has unveiled a voluntary plan to repurchase up to 5.5 million H shares on the open market, with total spending capped at RMB100 million and funded from existing cash resources. The buyback proposal, which reflects management’s confidence in the company’s long-term growth and aims to enhance shareholder value, remains subject to board approval and a repurchase mandate from shareholders at the May 22, 2026 annual general meeting.

The company has pledged to conduct any repurchases within Hong Kong listing and takeover rules, including limits on pricing and maintaining sufficient public float to avoid triggering a mandatory general offer. Management emphasized that the timing, size and execution of any buybacks will depend on market conditions, and warned investors there is no assurance that share repurchases will ultimately be carried out, urging caution in trading its securities.

More about LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong as a non-Hong Kong company. It operates in the medical technology sector, focusing on the development and commercialization of medical devices and related technologies for healthcare markets.

Average Trading Volume: 429,026

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.48B

Find detailed analytics on 2291 stock on TipRanks’ Stock Analysis page.